BLBenjamin Lowentritt

Benjamin Lowentritt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Lowentritt has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US

    by Mehmet A. Bilen, Gordon Brown, Mukul Singhal, Carmine Rossi, Dominic Pilon, Courtney D. Longfield, Benjamin Lowentritt

  • Open Access

    Advancing metastatic prostate cancer care: best practices and future directions in molecular testing

    by Elena Castro, Jie-Fu Chen, Ben Lowentritt, Partha Das, Ramin Dowlati, David Olmos

  • Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer

    by Mehmet A. Bilen, Neal Shore, Sabree Burbage, Carmine Rossi, Lilian Diaz, Ibrahim Khilfeh, Yuxi Wang, Gordon Wong, Dominic Pilon, Gordon Brown, et al.


  • Open Access

    Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States

    by Benjamin Lowentritt, Sreevalsa Appukkuttan, Nicholas Lazarou, Lorraine O’dOnnell, James Eller, Katie Grant, Israel Arango-Hisijara, Bashir Kalayeh, Lauren Curry, Audrey Himes, et al.

    This study examines patient clinical profiles and real-world utilization patterns of darolutamide doublet (+ADT alone) and triplet therapy (+ADT and docetaxel) for the treatment of metastatic hormone-sensitive prostate cancer. This was a retrospective, observational study using the Precision Point Specialty Analytics (Specialty Networks) patient population health management platform to identify adult men with metastatic hormone-sensitive prostate cancer who received darolutamide doublet or triplet therapy between July 1, 2019, and March 31, 2023. Of 420 patients, 249 received doublet therapy and 171 received triplet therapy. Most patients included in the analysis were non-Hispanic White (doublet therapy: 67.1%; triplet therapy: 63.2%) and had Medicare insurance (doublet therapy: 77.5%; triplet therapy: 54.4%). Comorbid conditions were common, with hypertension (32.4%) and diabetes (15.0%) being the most prevalent. The mean prostate-specific antigen value at the index date was 20.9 ng/mL (standard deviation 87.2 ng/mL) in the doublet therapy cohort and 66.4 ng/mL (standard deviation 286.4 ng/mL) in the triplet therapy cohort. Most patients presented with high-grade cancer at diagnosis, with 50.6% of patients in the doublet therapy cohort and 74.2% of patients in the triplet therapy cohort having a high (≥8) Gleason score at diagnosis. The median duration of darolutamide treatment in the doublet therapy cohort was 48 weeks and in the triplet therapy cohort was 46 weeks. This study demonstrated that darolutamide doublet therapy and triplet therapy are used ubiquitously across community urology practices in the United States for the treatment of metastatic hormone-sensitive prostate cancer.


  • Open Access

    Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology

    by Michael Fabrizio, Paul Monk, Paul Sieber, Jason Hafron, Lawrence Karsh, Bryan Mehlhaff, Christopher Pieczonka, Benjamin Lowentritt, Katie Grant, Lorraine O'DOnnell, et al.

    Background Sipuleucel-T, approved for metastatic castration-resistant prostate cancer (mCRPC) in 2010, improves survival, but real-world outcomes data are limited. We compared baseline characteristics and real-world overall survival (rwOS) of patients treated with and without sipuleucel-T for mCRPC. Methods This multicenter, retrospective observational study analyzed electronic medical records from United States community urology clinics. Men aged ≥ 18 years diagnosed with mCRPC between January 2010 and May 2019 were divided into 2 groups based on whether they received sipuleucel-T. Propensity score matching (PSM) was used to balance the cohorts by age, race, region, prostate-specific antigen (PSA) level, and Gleason score. Results Among 11 265 patients, 47% received sipuleucel-T. They were younger, had lower PSA levels, and better performance scores than those who did not receive it. Median follow-up was 3 years for treated and 1 year for untreated patients. Sipuleucel-T recipients had markedly better 5-year survival rates (28% vs 12%) and lived a median of 20 months longer (44 vs 24 months; P < .001). Black/African American patients had the highest 5-year survival (24%) compared with White (20%) or other groups (17%). After PSM, the median rwOS was 43 months with sipuleucel-T and 25 months without it, with an 18-month survival advantage (hazard ratio 1.66; 95% CI 1.54–1.78). Conclusions Sipuleucel-T was associated with significantly improved mCRPC survival in real-world settings, especially among Black/African American patients. Findings are subject to limitations, including selection bias and unmeasured confounding, but reinforce the therapeutic and life-prolonging benefit of sipuleucel-T.

  • Open Access

    How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study

    by Benjamin H. Lowentritt, Albert Chau, Phillip Davis

    Objectives: To explore the impact of different standard of truth (SoT) methodologies on efficacy endpoints traditionally used in clinical trials of diagnostic radiopharmaceuticals, using data from the SPOTLIGHT study (NCT04186845) in patients with recurrent prostate cancer. Methods: Data from patients with baseline prostate-specific antigen (PSA) ≤ 5 ng/mL, who underwent 18F-flotufolastat imaging and had data for SoT determination, were reviewed. Majority-read patient level endpoints (verified detection rate [VDR] and patient-level positive predictive value [PPV]), and region-level PPV (in the prostate/prostate bed, pelvic lymph nodes, and extrapelvic sites) according to on-study reads by three blinded readers, were stratified by the SoT methodology (histopathology; post-PET confirmatory imaging; baseline/historic conventional imaging) used by the independent Truth Panel to verify 18F-flotufolastat-avid lesions. Differences between SoT groups for each endpoint were compared using a chi-square test (statistically significant if p < 0.0167). Results: Our analysis included 297 patients (median baseline PSA = 0.8 ng/mL): 56% (n = 166) had post-PET confirmatory imaging, 26% (n = 78) had baseline/historic conventional imaging, and 18% (n = 53) had histopathological confirmation of ≥1 PET-positive lesion. For all endpoints assessed, the highest majority-read values were achieved with histopathology SoT. For histopathology versus baseline/historic conventional imaging, VDR (77%) was 3.6-fold higher (p < 0.0001), patient-level PPV (79%) was 2.2-fold higher (p < 0.0001), and region-level PPV (50%) was 3.7-fold higher in the prostate/prostate bed (p = 0.009); smaller increases were seen in majority-read PPV in the pelvic lymph nodes (77%; 1.5-fold) and other sites (75%; 1.3-fold), but these were not of statistical significance. Conclusions: These data illustrate how SoT methods can substantially impact efficacy endpoints traditionally used in clinical trials of diagnostic radiopharmaceuticals. Notably lower endpoint values are achieved with imaging SoT than with histopathology.


  • Open Access

    Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study

    by Benjamin H. Lowentritt, Ashesh B. Jani, Brian T. Helfand, Edward M. Uchio, Michael A. Morris, Jeff M. Michalski, Albert Chau, Phillip Davis, Brian F. Chapin, David M. Schuster